Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab biosimilar - R-Pharm

Next Previous
Drug Profile

Cetuximab biosimilar - R-Pharm

Alternative Names: Erbitux biosimilar - R-Pharm; RPH-002

Latest Information Update: 25 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator R-Pharm
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Head and neck cancer; Squamous cell cancer

Most Recent Events

  • 30 May 2025 Phase-I clinical trials in Head and neck cancer (Combination therapy, Late-stage disease, First-line therapy, Inoperble/Unresectable, Recurrent) in Russia (IV), Before May 2025
  • 30 May 2025 Efficacy, adverse events and pharmacokinetics data from phase I trial in Head and neck cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 08 Oct 2021 Phase III trial is still ongoing for Head and neck cancer and Colorectal cancer in Russia (R-Pharm pipeline, October 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top